However, we would like to emphasize that 4/9 BRCA1 or BRCA2 pathogenic mutation carriers and all CHEK2 P/LP variant carriers would not be eligible for germline genetic testing according to the current guidelines, despite the fact that all other mutation carriers (except for one patient with the founder c.5266dupC BRCA1 mutation) had a positive family cancer history and four also developed secondary tumors alongside solitary or multiple melanoma (Table 3). The gene discussed is CHEK2; the disease is cancer.